The 2028 R&D Tax Incentive changes: what is proposed and who is worried
The 2028 R&D Tax Incentive reform: higher core rates, no supporting R&D, refunds for young firms only, a $50,000 minimum, and where the bill stands.
From 1 July 2028 the government plans to raise R&D Tax Incentive rates for core research, stop paying for supporting R&D, limit cash refunds to young companies, and require small claims to go through a registered research service provider. The changes were announced in the 2026-27 Budget and are in a bill that, as of 17 November 2026, has passed the House of Representatives but not the Senate, so none of it is law yet (Parliament of Australia).
Until that date, today's rules stand. Here is what is proposed, where it came from, and who is worried about it.
What is proposed
| Rule | Now | Proposed from 1 July 2028 |
|---|---|---|
| Core R&D offset rates | Tax rate + 18.5% (small) or + 8.5% / 16.5% (large) | Each rises by 4.5 percentage points |
| Supporting R&D | Eligible | No longer eligible |
| Refundable offset turnover threshold | Under $20 million | Under $50 million |
| Who gets a refund | Any company under the threshold | Firms under 10 years old (up to 15 for biotech and medtech in the bill); older firms get the same rate, non-refundable |
| Intensity threshold for the higher non-refundable rate | 2% | 1.5% |
| Minimum spend | $20,000, waived for RSPs and CRCs | $50,000; below that, only R&D with a registered RSP or CRC is eligible |
| Expenditure cap | $150 million | $200 million |
Sources: Budget Paper No. 2, 2026-27 and the Treasurer’s second reading speech of 27 October 2026. The Budget paper describes the rate rise as increasing the offset for core R&D expenditure by around 25 to 50 per cent.
Why the government is doing it
The measure is described as the first stage of the government's response to Ambitious Australia, the Strategic Examination of Research and Development. That review found Australia's gross spending on R&D had fallen from a peak of 2.24% of GDP in 2008-09 to 1.69% in 2023-24, among the lowest in the OECD (The Conversation via UTS). The government says the reforms will add $400 million a year of R&D by young firms (budget.gov.au).
The Budget paper puts the overall effect at $910.0 million less in receipts and $1.6 billion less in payments over five years from 2025-26, with $2.8 million for the ATO to put it in place. SmartCompany noted the higher cap still falls short of the review's call to remove the cap altogether (SmartCompany, May 2026).
How the bill changed after consultation
Treasury released draft legislation for comment from 11 to 28 September 2026. The draft added longer refundability, up to 15 years, for firms doing R&D related to therapeutic goods, and asked whether clinical manufacturing should be eligible (Treasury consultation).
The bill introduced on 27 October 2026, the Treasury Laws Amendment (Tax Reform No. 4) Bill 2026, gives biotechnology and medical technology firms access to the refundable offset for up to 15 years and adds a power for the Treasury minister, in consultation with the industry minister, to prescribe activities “integral to core R&D”. The department will consult on those activities in early 2027 (Treasurer’s media release).
Who is worried
The removal of supporting R&D is the sharpest point for hardware companies. Sam Ringwaldt, CEO and co-founder of Conry Tech, wrote after the Budget: “The headline rate increase to the R&D tax incentive is welcome and real. But buried in the detail is the removal of supporting R&D eligibility. For a software company, that is a rounding error.” (SmartCompany, May 2026) His point is that the change costs hardware companies far more than software companies.
The 10-year refund limit worries biotech. Ian Nisbet, chief executive of cell therapy company Cartherics, told Capital Brief: “You’re only just getting started after 10 years. If you’re lucky, you’re going into the clinic ... You’re starting to incur really large expenses at that point — and you’re unlikely to have any revenue.” (Capital Brief, May 2026) The bill's 15-year allowance for biotech and medtech came after that criticism.
On 30 June 2026, 17 industry groups, including AusBiotech, Science & Technology Australia and Cicada Innovations, wrote to the Treasurer asking for consultation on the refund limit and on supporting R&D (SmartCompany, July 2026). The bill also bundles other tax changes, and Startup Daily reported the Greens had threatened to withhold support unless oil and gas companies were excluded, which could complicate its path through the Senate (SmartCompany, October 2026).
What to do now
- Claim under today's rules for work done before July 2028. Nothing changes for current income years.
- Sort your activities into core and supporting now. If the bill passes, supporting work stops earning the offset. Knowing the split tells you how much the higher core rate is worth to you.
- Check your company's age. If you will be 10 years old or more by 2028-29 and rely on cash refunds, plan for the offset becoming non-refundable.
- Plan small projects around an RSP. If you run R&D under $50,000 a year, budget to use a registered research service provider or a CRC. See our RSP explainer.
- Write the hypothesis down. Higher rates for core R&D mean more scrutiny of what counts as core. Record the hypothesis, the test and the result for each activity as you go.
We will update this page when the Senate votes. This is general information, not tax advice.
Reader questions
- Are the 2028 R&D Tax Incentive changes law?
- Not yet. As of 17 November 2026 the bill had passed the House and was before the Senate (Parliament of Australia).
- When do the changes start?
- 1 July 2028, for the measures in the bill. Claims for earlier years follow today's rules.
- Will supporting R&D still be claimable?
- Not under the proposal. Supporting R&D expenditure stops being eligible from 1 July 2028, while core R&D rates rise by 4.5 points.